QMSR Is Changing What “Good Audits” Really Mean

What Is QMSR?

The Quality Management System Regulation (QMSR) is the FDA’s updated quality regulation for medical device manufacturers, taking effect on February 2, 2026. It replaces the current Quality System Regulation and formally aligns FDA requirements with ISO 13485:2016, meaning FDA inspections will now evaluate quality systems using many of the same expectations applied during ISO audits.

Why Internal Audits Will Be Scrutinized More Closely

Under QMSR, internal audits are no longer just about proving a procedure exists. FDA investigators will be looking at whether audits are risk-based, conducted on schedule, performed by independent auditors, and followed by meaningful corrective actions. Missed audits, shallow findings, or CAPAs that close issues without fixing root causes are all likely to raise red flags during inspections.

Supplier Audits Are Now a Risk Conversation

Supplier oversight will also be examined through a stronger risk-based lens. Companies will need to clearly explain how suppliers are evaluated, why certain suppliers are audited (or not), and how those decisions tie back to product risk. Weak supplier documentation, outdated approved supplier lists, or missing quality agreements, especially for critical suppliers, an quickly turn into FDA-483 observations.

The Bigger Shift QMSR Is Forcing

More than anything, QMSR changes expectations around intent. Audits can’t exist just to satisfy a requirement or survive an inspection. FDA is signaling that audits should actively surface issues, drive improvement, and show evidence of real oversight. Companies that treat audits as tools, not paperwork, will be far better positioned under the new regulatory reality.

Final Takeaway: How can KeyPedia Help?

QMSR makes one thing clear: FDA is paying closer attention to how audit decisions are made, not just how they’re documented. Companies that can show clear risk-based reasoning, consistent execution, and real follow-through will be in a much stronger position during inspections. If you’re not confident you could explain, or defend, your audit decisions to an FDA investigator, now is the time to take a closer look.

At GKS, we help teams gain visibility into their quality systems so audit decisions are easier to justify, easier to track, and easier to stand behind when regulators come knocking.